The Dana Farber Consortium Protocol (DFCP) for the treatment of adolescents and young adults with acute lymphoblastic leukemia: a single institution experience in Saudi Arabia

This retrospective study sought to evaluate the feasibility of using the Dana Farber Consortium Protocol (DFCP) in Saudi adolescents and young adult patients (AYA) with acute lymphoblastic leukemia (ALL). The 3-year leukemia-free survival (LFS) and overall survival (OS) rates were 68% and 70%, respectively. Toxicities included infection, mortality during induction, and pancreatitis, but the incidence and severity of osteonecrosis were less than in Western populations, and no venous thromboembolism (VTE) was found with the use of enoxaparin prophylaxis.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research